ANYTHING going on here maybe.......................................
Bristol-Myers has also effectively killed a phase 3 trial of the IDO1-PD-1 combination as a first-line treatment of patients with metastatic or unresectable melanoma, the same indication targeted in the Incyte study: http://ow.ly/VB8030jLUFS $BMY
